Ovarian cancer often goes undetected until it spreads to other areas. In its late stages, it's harder to treat. Now there's an unconventional treatment being used to get rid of it. When her stomach ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer. Among patients with platinum-sensitive peritoneal ...

Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

Credit: Getty Images. Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests. Adding hyperthermic intraperitoneal ...

Barbara Franklin loves new beginnings. Ten years ago, Franklin beat breast cancer. Now, at the age of 65, she's battling advanced ovarian cancer. "I was stage four, and what symptoms did I have? A ...

Please provide your email address to receive an email when new articles are posted on . Adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery did not significantly prolong PFS or ...

Neoadjuvant chemotherapy followed by interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves progression-free survival (PFS) and overall survival ...

Because of the predominant intraperitoneal (IP) spread of epithelial ovarian cancer (OC), IP chemotherapy has been investigated for more than three decades, but it is not widely adopted for several ...

Tracy Gosson was shocked when she learned in 2019 that she had stage 4 ovarian cancer. With the cancer growing “at a lightning pace,” she underwent her first round of chemotherapy within three weeks ...